Fitaro 2.4mg Injection

✔️ Uses of Fitaro 2.4mg Injection

Type 2 Diabetes Mellitus

✔️ Side Effects of Fitaro 2.4mg Injection

• Diabetic eye disease (retinopathy)
• Nausea or vomiting
• Diarrhea
• Hypoglycemia (low blood sugar)
• Upset stomach or indigestion
• Gastritis (inflamed stomach)
• Stomach ache
• Reflux or heartburn
• Bloating
• Constipation
• Tiredness
• Reduced appetite
• Gas (flatulence)
• Increased pancreatic enzymes (lipase and amylase)

✔️ Diet & Lifestyle Advice:

• Regular meals; avoid long gaps.
• Monitor blood sugar levels regularly.
• 150 min of moderate-intensity physical activity and 15 minutes of exercise per week.
• Gradual weight loss for a healthy BMI.
• Replace refined carbohydrates with whole grains.
• Omega-3 fatty acid-containing oils.
• Low-fat dairy; reduce saturated fats.
• Quit smoking; limit alcohol intake.

✔️ Quick Suggestions:

• Take SEMAGLUTIDE as prescribed, even if blood sugar is controlled.
• Regular blood sugar monitoring.
• Pancreatic enzyme monitoring is recommended.
• Avoid prolonged fasting; be aware of hypoglycemia symptoms.
• Type 2 Diabetes: Insufficient insulin production; control blood sugar for preventing complications.

✔️ Type 2 Diabetes:

• The body inadequately produces or uses insulin.
• Elevated blood sugar can lead to heart disease, renal disease, eye abnormalities, and poor limb circulation.

✔️ Pharmacology

Glucagon-like peptide-1 (GLP-1) agonists, which are classified as incretin mimetics, play a crucial role in glucose metabolism by affecting various aspects of pancreatic and gastrointestinal functions. Here's a breakdown of the actions of GLP-1:

Enhanced Glucose-Dependent Insulin Secretion:

• GLP-1 agonists enhance the secretion of insulin from pancreatic beta-cells.
• Importantly, this insulin secretion is glucose-dependent. In other words, GLP-1 increases insulin release in response to elevated blood glucose levels, helping to regulate blood sugar.

Suppression of Glucagon Secretion:

• GLP-1 agonists suppress the release of glucagon from pancreatic alpha-cells.
• Glucagon typically raises blood glucose levels by stimulating the liver to convert stored glycogen into glucose. By inhibiting this action, GLP-1 helps prevent excessive glucose production.

Slowing Gastric Emptying:

• GLP-1 agonists slow down the emptying of the stomach contents into the small intestine.
• This delayed gastric emptying helps to regulate the rate at which nutrients, including glucose, are absorbed from the digestive system into the bloodstream. Slower nutrient absorption contributes to better blood glucose control after meals.

In summary, the actions of GLP-1 agonists contribute to improved glycemic control in individuals with type 2 diabetes. By promoting glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, and slowing gastric emptying, these medications help maintain more stable blood glucose levels throughout the day. This makes GLP-1 agonists valuable therapeutic options for managing type 2 diabetes, especially when lifestyle modifications and other oral medications are not sufficient.

✔️ Dosage

Dosage:

• 0.25 mg SC week for 4 weeks initially: Start with this lower dosage for the first 4 weeks.
• Increase to 0.5 mg qWeek: If glycemic control is not achieved after at least 4 weeks on the 0.25 mg dose, increase to this dosage.
• Further Increase to 1 mg qWeek: If glycemic control is still not achieved after at least 4 weeks on the 0.5 mg dose, the dosage can be increased to 1 mg qWeek.

Hepatic Impairment:

• No dosage adjustment is required for individuals with hepatic impairment.

Child Dose:

• Safety and efficacy are not established for individuals under 18 years. This medication is not indicated for use in children.

Renal Dose:

Renal Impairment:

• No dosage adjustment is required for individuals with renal impairment.

✔️ Administration:

Subcutaneous (SC) Administration:

• Administer subcutaneously to the abdomen, thigh, or upper arm.
• Injection should be given once weekly on the same day each week.
• Can be administered at any time of the day, with or without meals.
• The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 2 days (>48 hours).
• Use a different injection site each week when injecting in the same body region.

✔️ Interaction

Drug-Drug Interactions:

• Interaction with hormonal medications, oral anticoagulants, certain anti-diabetic medications, anti-cancer medications, and certain antibiotics.
• Discuss potential interactions with the doctor.

Drug-Food Interactions:

• No established interactions with food.

Drug-Disease Interactions:

• May interact with conditions such as suicidal behavior, thyroid cancer, GI adverse events, hypoglycemia, pancreatitis, and retinopathy.

✔️ Contraindications

Personal or Family History of MTC:

• Individuals with a personal history of MTC.
• Individuals with a family history of MTC.

Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2):

• Patients with MEN 2, a genetic disorder associated with the development of certain endocrine tumors.

Known Hypersensitivity to Semaglutide:

• Individuals who have previously shown hypersensitivity reactions to Semaglutide.
• Allergic reactions may include symptoms such as rash, itching, swelling, severe dizziness, or difficulty breathing.

✔️ Pregnancy & Lactation

There is limited data on Semaglutide use in pregnant women. Semaglutide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There are no data on the presence of Semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. Discontinue Semaglutide in women at least 2 months before a planned pregnancy due to the long washout period for Semaglutide.

✔️ Precautions & Warnings

• Allergic Reaction
• Gastrointestinal Effects
• Pancreatic Inflammation
• Pregnancy and Breastfeeding

✔️ Storage Conditions

Do not freeze the Fitaro Injection. Do not use it if it has been frozen. Store your Fitaro Injection in the refrigerator at 2°C to 8°C (36°F to 46°F). After the first use of Fitaro Injection, the pen can be stored for 56 days in a refrigerator (2°C to 8°C).